GlassScriptPhysician profile
Elise Bolstad
NPI 1962029280
$4,659.25
in general payments reported to CMS, 2019-2025
16 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $235 · 2021: $632 · 2022: $954 · 2023: $1,864 · 2024: $558 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Travel and Lodging: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.40 |
| Travel and Lodging | $1,189.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,393.94 | 2021-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Novartis Pharmaceuticals Corporation | $440.48 | 2020-2023 | |
| Harrow Eye, LLC | $255.88 | 2024-2025 | Vevye |
| Coopervision INC. | $238.95 | 2020-2024 | Myday Contact Lens |
| Dompe US, INC. | $200.19 | 2021-2025 | Oxervate |
| Abbvie INC. | $198.78 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Tarsus Pharmaceuticals, INC. | $183.98 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $136.50 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $116.66 | 2021-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.51 | 2020-2021 | |
| Oyster Point Pharma, INC. | $107.84 | 2022-2024 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $98.06 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $69.48 | 2021 | |
| Allergan, INC. | $65.61 | 2022 | |
| Glaukos Corporation | $24.04 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $19.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Bolstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.